{
  "id": 12036203,
  "title": "Trial results show no survival benefit with the use of proton therapy in patients with advanced hepatocellular carcinoma",
  "url": "https://urgent.news/2026/10/05/trial-results-show-no-survival-benefit-with-the-use-of-proton-therapy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T00:30:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-trial-results-survival-benefit-proton.html"
  },
  "original_language": "en",
  "account": "A recent clinical study has found no benefit in using proton therapy for patients with advanced hepatocellular carcinoma (HCC) compared to traditional photon therapy. The NRG Oncology NRG-GI003 trial, which enrolled 115 patients and assigned them to proton or photon therapy, showed no improvement in overall survival, progression-free survival, or local progression. Although proton therapy resulted in fewer severe side effects, the difference was not statistically significant. The findings suggest that proton therapy should be further investigated for specific subgroups of HCC patients, and future studies should examine potential quality of life improvements and reduced side effects associated with proton therapy.",
  "summary": "Initial results of the NRG Oncology NRG-GI003 clinical study comparing proton and photon therapy for patients with advanced hepatocellular carcinoma (HCC) indicate that proton therapy did not improve the primary objective of overall survival (OS). At the planned interim analysis, the trial was released for reporting after it crossed the futility boundary. Proton therapy also did not improve the…",
  "key_points": [
    "No survival benefit found with proton therapy for advanced HCC",
    "NRG Oncology NRG-GI003 trial involved 115 patients",
    "Proton therapy reduced severe side effects, but difference was not significant"
  ],
  "editors_take": "This study's finding that proton therapy offers no survival benefit for advanced HCC patients challenges its potential as a go-to treatment, but leaves room for exploring its benefits in specific patient subgroups.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}